IDENTIFICATION OF PAX3-FOXO1 FUSION ONCOGENE DEGRADERS USING A NOVEL HIBIT SYSTEM FOR THE THERAPY OF FUSION-POSITIVE RHABDOMYOSARCOMA

The Geneva Foundation

Investigators